Your browser is no longer supported. Please, upgrade your browser.
SHPG Shire plc daily Stock Chart
Shire plc
Index- P/E22.58 EPS (ttm)7.94 Insider Own0.10% Shs Outstand304.67M Perf Week3.58%
Market Cap54.60B Forward P/E11.41 EPS next Y15.70 Insider Trans0.00% Shs Float300.17M Perf Month4.49%
Income2.42B PEG3.83 EPS next Q3.73 Inst Own32.70% Short Float0.64% Perf Quarter1.33%
Sales15.70B P/S3.48 EPS this Y160.00% Inst Trans43.34% Short Ratio1.12 Perf Half Y5.12%
Book/sh122.40 P/B1.46 EPS next Y4.06% ROA7.20% Target Price200.27 Perf Year13.93%
Cash/sh0.68 P/C263.62 EPS next 5Y5.90% ROE13.00% 52W Range123.73 - 182.47 Perf YTD2.96%
Dividend1.06 P/FCF15.68 EPS past 5Y7.50% ROI4.30% 52W High-1.79% Beta0.94
Dividend %0.59% Quick Ratio0.50 Sales past 5Y27.30% Gross Margin70.30% 52W Low44.83% ATR3.53
Employees23044 Current Ratio0.90 Sales Q/Q4.70% Oper. Margin21.20% RSI (14)58.62 Volatility1.22% 1.35%
OptionableYes Debt/Eq0.41 EPS Q/Q-3.50% Profit Margin30.60% Rel Volume0.00 Prev Close179.20
ShortableYes LT Debt/Eq0.30 EarningsJan 31 BMO Payout5.50% Avg Volume1.70M Price179.20
Recom2.10 SMA203.85% SMA502.39% SMA2006.19% Volume1 Change0.00%
Dec-20-18Downgrade William Blair Outperform → Mkt Perform
Dec-11-18Downgrade SunTrust Buy → Hold
Sep-07-18Downgrade Berenberg Buy → Hold
Sep-04-18Downgrade Bernstein Outperform → Mkt Perform
May-11-18Resumed Kepler Buy
Feb-20-18Downgrade JP Morgan Overweight → Neutral
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $201 → $181
Feb-14-18Upgrade Bernstein Mkt Perform → Outperform
Dec-20-17Downgrade Liberum Buy → Hold
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Jan-15-19 01:02PM  Takeda Pharmaceutical CEO Talks Big Pharma Trends
Jan-11-19 01:00PM  Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange GlobeNewswire
Jan-09-19 03:09AM  De-listing and cancellation of trading of Shire Shares GlobeNewswire
Jan-08-19 12:30PM  Director/PDMR Shareholding GlobeNewswire
12:15PM  5 Companies Hit 52-Week Highs
08:15AM  The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga
07:27AM  [$$] Takeda completes £46bn acquisition of Shire Financial Times
04:29AM  How Takeda's $62 Billion Shire Deal Reshapes Pharma World Bloomberg
02:00AM  Scheme becomes effective GlobeNewswire
Jan-07-19 08:46PM  Takeda closes $62B purchase of Shire, creating largest Mass. biotech employer American City Business Journals
07:09PM  Scheme becomes effective GlobeNewswire
12:00PM  Holding(s) in Company GlobeNewswire
Jan-03-19 09:01AM  Bristol-Myers Finds a $74 Billion Biotech Bargain Bloomberg
07:15AM  Court sanction of the Scheme GlobeNewswire
Jan-02-19 10:15AM  Holding(s) in Company GlobeNewswire
05:30AM  Total voting rights GlobeNewswire
Dec-31-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-28-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
02:00AM  Holding(s) in Company GlobeNewswire
Dec-27-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-24-18 04:50AM  Holding(s) in Company GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-21-18 11:00AM  Director Declaration GlobeNewswire
06:30AM  Holding(s) in Company GlobeNewswire
Dec-20-18 04:02PM  3 Stocks Seth Klarman and Protege David Abrams Both Own
08:00AM  Director/PDMR Shareholding GlobeNewswire
07:00AM  Form 8 (DD) - Susan Kilsby GlobeNewswire
07:00AM  Form 8 (DD) - Steven Gillis GlobeNewswire
07:00AM  Form 8 (DD) - Sara Mathew GlobeNewswire
07:00AM  Form 8 (DD) - Olivier Bohuon GlobeNewswire
07:00AM  Form 8 (DD) - Ian Clark GlobeNewswire
07:00AM  Form 8 (DD) - Gail Fosler GlobeNewswire
07:00AM  Form 8 (DD) - David Ginsburg GlobeNewswire
07:00AM  Form 8 (DD) - Albert Stroucken GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-17-18 07:00AM  FDA approves Shires Motegrity (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) GlobeNewswire
03:04AM  Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda to Baa2; outlook stable Moody's
Dec-14-18 08:00AM  Director/PDMR Shareholding GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-13-18 02:04AM  Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT Thomson Reuters StreetEvents
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-12-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-11-18 12:26PM  Shire, Abbott Labs May Pace Healthcare Stocks in 2019
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-07-18 03:38PM  Most Important Mergers and Acquisitions of 2016 Investopedia
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-05-18 09:54PM  Takeda Downgrade Looms After Shareholders Approve Shire Deal Bloomberg
08:51AM  Takeda's Long Battle for $62 Billion Shire Deal Gets Victory Bloomberg
08:50AM  Is the Options Market Predicting a Spike in Shire (SHPG) Stock? Zacks
06:03AM  Takeda, Shire shareholders approve $62B tie-up American City Business Journals
04:10AM  [$$] Takeda wins shareholder approval for £46bn Shire acquisition Financial Times
03:57AM  Asian Stocks Decline Even After China Expresses Confidence to Reach Trade Deal
02:00AM  Rule 2.9 Announcement GlobeNewswire
12:02AM  [$$] Takeda Shareholders Approve $62 Billion Shire Bid The Wall Street Journal
Dec-04-18 12:20PM  Holding(s) in Company GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Dec-03-18 09:47AM  Shire's Takhzyro Gets European Nod for Hereditary Angioedema Zacks
02:00AM  Total voting rights GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
02:00AM  Shire Receives European Approval for TAKHZYRO (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema GlobeNewswire
Nov-29-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-28-18 11:02PM  [$$] Climate change in Somaliland you can touch it Financial Times
08:50AM  Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-27-18 11:30AM  Shire plc: JAMA Publishes Complete Results of Phase 3 HELP Study Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-26-18 07:00AM  Form 8 (DD) - Shire plc GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-22-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-21-18 09:36AM  Shire-Takeda Deal Gets Phase I Conditional European Approval Zacks
03:06AM  EU approves Takeda buying Shire, on divestment condition Reuters
Nov-20-18 08:15PM  Takeda Heads to Shire Vote With Backing from EU, Advisory Groups Bloomberg
10:39AM  Shire-Takeda deal gets conditional EU approval, heads to shareholders American City Business Journals
09:15AM  Shire plc: Phase I conditional clearance by the European Commission GlobeNewswire
09:15AM  EU approves Takeda buying Shire, on divestment condition Reuters
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-19-18 09:08PM  [$$] EU clears Takeda-Shire deal with conditions Financial Times
07:54PM  Takeda's Dissident Holders Keep Trying to Kill Shire Deal Bloomberg
08:53AM  Takeda Moves Quickly to Sell Dollar Bonds for Shire Plc Deal Bloomberg
Nov-16-18 04:19AM  [$$] Takeda dissident investors make last push to block Shire deal Financial Times
02:00AM  Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting GlobeNewswire
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-15-18 08:21PM  Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade Moody's
Nov-14-18 04:15PM  David Abrams Buys Shire, Boosts Lithia Motors
12:11PM  David Abrams Buys 3 Stocks in 3rd Quarter
08:02AM  Shire's Filing Accepted by FDA for Gattex's Label Expansion Zacks
02:00AM  Rule 2.9 Announcement GlobeNewswire
Nov-13-18 05:20PM  Daniel Loeb Purchases 7 Stocks in 3rd Quarter
07:00AM  U.S. FDA Accepts for Filing Shires Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel Syndrome GlobeNewswire
Nov-12-18 01:39PM  Takeda's Shire takeover to bring $963 million fee bonanza Reuters
04:00AM  Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Reuters
03:59AM  Takeda sets vote date, aims to close $62 billion Shire deal on January 8 Reuters
02:54AM  [$$] Takeda sets date for shareholder vote on £46bn Shire deal Financial Times
02:00AM  Rule 2.9 Announcement GlobeNewswire
02:00AM  Publication of Scheme Document GlobeNewswire
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.